Systagenix Wound Management has appointed Dr Robert Snyder, a leading expert in wound care, as its new Medical Director.
A practicing podiatrist and wound specialist, Dr Snyder will underpin the company’s already impressive clinical evidence credentials by developing close relationships with major specialist organisations and thought leaders in the wound care field, worldwide. As an internationally recognised, well published and distinguished wound care practitioner, his first project will be to form and lead a new international Systagenix Medical Advisory Board that will meet at specific intervals to provide feedback, input and guidance on company clinical and commercial strategies.
Dr Snyder, a professor (adjunct) at Temple University College of Podiatric Medicine, will also be responsible for the review and management of all current and new clinical evidence to support many of the company’s key departments, including Research and Development, Professional Education, Medical Affairs and Marketing. Maintaining his strong links with clinical practice, Dr Snyder will continue to treat patients at his private practice and serve on various professional medical bodies and associations linked to wound care.
Dr Snyder is an experienced and sought-after speaker at major international meetings and will be representing Systagenix at such events, as well as working with members of the Medical Advisory Board and other product champions to develop a professional education speaker bureau. These individuals will lecture at seminars, congresses and meetings, both externally and within the company, to ensure the highest possible standard of education, not only about wound care, but also the new technologies being developed and pioneered by Systagenix.
Systagenix was formed by a management buyout of the Johnson & Johnson Professional Wound Care business which had a 75-year heritage. Systagenix has very clear objectives to become the world’s strongest and most admired wound care company. The business has the history and knowledge, which together with its experienced management team, will ensure that advanced wound care treatments are available to help clinicians offer the best clinical outcomes for their patients.
Systagenix’s CEO, Steve Atkinson comments: “We know our customers are looking for products that provide the desired results and outcomes for their patients. By offering a comprehensive wound care portfolio based on research and clinical evidence, I believe that Systagenix meets those needs.. With Dr Snyder joining our team as Medical Director, we continue to strengthen our expertise and relationships with major industry thought leaders, serving to enhance our clinical, professional education and product development plans for the future.”
“I am delighted to be joining such a reputable company, which is truly committed to putting excellent resources behind developing the next generation of wound care products and services. I see this as a great opportunity to leverage my wound care background to help Systagenix better understand the needs of clinicians and their patients,” says the new Medical Director, Dr Snyder.